A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Melanoma
Related studies linked through entity extraction aliases.
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients
- Status
- COMPLETED
- Phase
- NA
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
- Status
- COMPLETED
- Phase
- PHASE2
Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab and EDP1503 in Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
- Status
- TERMINATED
- Phase
- PHASE1
An Expanded Access Program for AM0010 (Pegilodecakin)
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
- Status
- COMPLETED
- Phase
- PHASE1
SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
- Status
- UNKNOWN
- Phase
- PHASE2
PD-L1 PET Imaging in Melanoma Patients
- Status
- COMPLETED
- Phase
- NA
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Circulating Tumor DNA Exposure in Peripheral Blood
- Status
- UNKNOWN
- Phase
- N/A